osimertinib
AstraZeneca Q1 Oncology Product Sales Increase 14 Percent Led by Tagrisso
Revenues from AstraZeneca's oncology segment in Q1 2022 totaled $3.64 billion, comprising around a third of the company's total revenues.
Hutchmed Receives $15M Milestone Payment From AstraZeneca in Orpathys Codevelopment Deal
The payment was triggered because Hutchmed is gearing up to launch a Phase III global trial of Orpathys in combination with Tagrisso in NSCLC patients with EGFR and MET aberrations.
RedCloud Bio to Begin Trial of Fourth-Generation EGFR Inhibitor in NSCLC Subgroup
The FDA accepted the firm's IND for H002, clearing the way for the Shanghai-based firm to begin Phase I/II trials in NSCLC patients with EGFR C797S resistance mutations.
AstraZeneca Q4 Oncology Revenues Grow 20 percent
The leading precision oncology product in the segment was Tagrisso, for which sales grew 14 percent during the quarter to $1.31 billion.
In Brief This Week: AstraZeneca, Daiichi Sankyo, Orgenesis, Amgen
News items for the week of Jan. 17, 2022.
Nov 12, 2021
AstraZeneca's Q3 Oncology Revenues Grow 18 Percent
Jul 29, 2021
AstraZeneca Q2 Revenues Increase 31 Percent
Jun 7, 2021
Oct 21, 2020